Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

Advances in Imaging and the Management of Myeloma Bone Disease

(2011) Evangelos Terpos et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

(2011) M A Dimopoulos et al.   LEUKEMIA

Lenalidomide: an update on evidence from clinical trials

(2010) Meletios-Athanassios Dimopoulos et al.   BLOOD REVIEWS

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

(2010) Andrew D Chantry et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Activin A and bone metastasis

(2010) Gaetano Leto   JOURNAL OF CELLULAR PHYSIOLOGY

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA